Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

RAY1225

Stage Phase 3Stale

Sponsor Guangdong Raynovent Biotech Co

Route oral and injection

Sources

registry, as of 2025-07-17Stale

https://clinicaltrials.gov/study/NCT06893016

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Guangdong Raynovent Biotech Co., Ltd. Enrollment 640. Conditions Obesity. The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.

ClinicalTrials.gov NCT06893016 protocol and results modules

registry, as of 2025-03-19Stale

https://clinicaltrials.gov/study/NCT06254261

A Study of RAY1225 in Participants With Obesity. Overall status RECRUITING. Phases PHASE2. Lead sponsor Guangdong Raynovent Biotech Co., Ltd. Enrollment 270. Conditions Obesity. The main purpose of this study is to learn more about the Tolerability of RAY1225 in participants with Obesity. The study will also explore the efficacy of RAY1225. The study will last about six months for each participant.

ClinicalTrials.gov NCT06254261 protocol and results modules

registry, as of 2026-03-05Stale

https://clinicaltrials.gov/study/NCT05835752

The Safety, Tolerability and Pharmacokinetic Study of RAY1225. Overall status COMPLETED. Phases PHASE1. Lead sponsor Guangdong Raynovent Biotech Co., Ltd. Enrollment 68. Conditions Obese; Healthy. This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225

ClinicalTrials.gov NCT05835752 protocol and results modules

registry, as of 2026-01-23Stale

https://clinicaltrials.gov/study/NCT07362030

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE1. Lead sponsor Guangdong Raynovent Biotech Co., Ltd. Enrollment 32. Conditions Obesity. The drug-drug interaction study had been designed to investigate the effect of RAY1225 on the pharmacokinetics of digoxin, Rosuvastatin and

ClinicalTrials.gov NCT07362030 protocol and results modules

Studies

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

Registry NCT06893016

Phase Phase 3

Status Recruiting

Enrollment 640

Start 2025-06-15

Primary completion 2026-06-15

Study completion 2026-09-15

Catalyst Primary completion. 2026-06-15. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

RAY1225 High Dose

Comparator placebo

Population Obesity

RAY1225 Medium Dose

Comparator placebo

Population Obesity

RAY1225 Low Dose

Comparator placebo

Population Obesity

Placebo

Population Obesity

A Study of RAY1225 in Participants With Obesity

Registry NCT06254261

Phase Phase 2

Status Recruiting

Enrollment 270

Start 2024-02-21

Primary completion 2025-12-20

Study completion 2025-12-20

Catalyst Primary completion. 2025-12-20. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

RAY1225 (cohort 1)

Comparator placebo

Population Obesity

Placebo (cohort 1)

Population Obesity

RAY1225 (cohort 2)

Comparator placebo

Population Obesity

Placebo (cohort 2)

Population Obesity

The Safety, Tolerability and Pharmacokinetic Study of RAY1225

Registry NCT05835752

Phase Phase 1

Status Completed

Enrollment 68

Start 2023-05-18

Primary completion 2024-03-01

Study completion 2024-03-23

RAY1225(Part A)

Regimen once weekly

Comparator placebo

Population Obese; Healthy

Placebo (Part A)

Regimen once weekly

Population Obese; Healthy

RAY1225 (Part B)

Regimen once weekly

Comparator placebo

Population Obese; Healthy

Placebo (Part B)

Regimen once weekly

Population Obese; Healthy

RAY1225(Part C)

Regimen once weekly

Comparator placebo

Population Obese; Healthy

Placebo (Part C)

Regimen once weekly

Population Obese; Healthy

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin

Registry NCT07362030

Phase Phase 1

Status Active, not recruiting

Enrollment 32

Start 2025-04-14

Primary completion 2025-12-27

Study completion 2026-03-30

Catalyst Primary completion. 2025-12-27. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Experimental 1

Population Obesity